Project Grant R44CA302283
Award Date 9/12/25
Completion Date 8/31/27
Dollars Obligated $1.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Lombard, IL 60148, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop new chemical probes capable of effectively targeting the "undruggable" c-MYC protein, which is implicated in driving the progression of castration-resistant prostate cancer (CRPC). The $177,209 award to Temple University aims to apply the university's Fluorine-Thiol Displacement Reaction (FTDR) stapling technology to rationally design c-MYC targeted peptide...
- This Project Grant award for $249,417.00 was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research federal grant program (CFDA 93.395) to support the development of a drug product called MT-125 for the treatment of recurrent high-grade glioblastomas (GBM). Glioblastoma is an aggressive and deadly form of brain cancer with a very poor prognosis. The award will fund preclinical studies and a Phase 0/1B dose escalation clinical trial of MT-125, a dual inhibitor of...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $1,233,778 Project Grant to Matrisome Bio, Inc. to develop an extracellular matrix-targeted theranostic radiopharmaceutical for treating metastatic lung cancer. The funding will support research and development efforts to create molecularly targeted drugs using nanobodies that specifically bind to disease-associated extracellular matrix proteins in lung tumors and metastases. This novel approach aims to...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the Mayo Clinic Jacksonville (a nonprofit corporation registered as Scott Lynch MD) to develop a first-in-class non-muscle myosin II (NMII) inhibitor, MT-125, for the treatment of glioblastoma. The $607,634 award, effective January 1, 2025 through December 31, 2029, supports research to uncover the mechanisms behind the synergistic effects of MT-125 when combined with...
- The National Cancer Institute, under the Cancer Treatment Research federal grant program (CFDA 93.395), awarded a $400,000 project grant to Nuago Therapeutics Inc. on June 9, 2025. The grant supports the development of a short RNA therapeutic to treat ovarian cancer. This research aims to develop a novel, targeted cancer therapy that can potentially overcome limitations of existing cancer treatments. The award has a projected completion date of May 31, 2026 and will be conducted at the company's...
- The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394), awarded a $399,444 Project Grant to Cancure LLC (Canzx Biotherapeutics) on August 1, 2025. The funding will support a feasibility study of a novel agent that aims to stimulate NK (natural killer) and CD8 T cells for potential use in treating solid tumors. The study seeks to address challenges with persistence and sustained function of these cell-based therapies in the solid...
- This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports the development of a novel, targeted small molecule inhibitor called TRE-515 by Trethera Corp, a clinical-stage biopharmaceutical company based in California. The $1,150,000 award will fund preclinical studies to evaluate TRE-515, which targets the deoxycytidine kinase (DCK) enzyme, as a potential combination therapy to prevent the DCK-mediated resistance mechanism in...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $2,253,869 to Celdara Medical, LLC to develop CM-HZ01, a novel non-alpha-IL2 therapeutic for the treatment of metastatic melanoma. The funding supports advancing CM-HZ01 to the Investigational New Drug (IND) application stage, with the goal of providing a best-in-class immunotherapy for patients with limited effective treatment options for this deadly form of skin cancer. The project...
- This $306,265 federal Project Grant, awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) on September 16, 2025, will fund the preclinical development of VAX024 - a novel, second-generation recombinant bacterial minicell-based targeted oncolytic in situ immunization (ISI) agent. VAX024 is designed to overcome limitations of current oncolytic viral therapies by leveraging the grantee's proprietary delivery technology to generate a sterile, user-friendly oncolytic...
- This federal Project Grant award, funded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), provides $400,000.00 to Onconaut Therapeutics Inc. to develop novel combination therapies for the treatment of colorectal cancer. The project aims to evaluate the efficacy of combining FOLFIRI chemotherapy with CHD1L inhibitors (OTI-600 series), which have demonstrated antitumor activity as single agents and potential synergistic effects when combined with...